Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: Role of SMVT

Venkata K. Yellepeddi, Ajay Kumar, Diane M. Maher, Subhash Chauhan, Kiran K. Vangara, Srinath Palakurthi

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Aim: The aim of this study was to prepare biotinylated PAMAM dendrimers loaded with cisplatin and to evaluate the cytotoxicity in ovarian cancer cell lines. Materials and Methods: Biotinylated and unconjugated dendrimer-cisplatin complexes were investigated for encapsulation efficiency, in vitro cytotoxic activity and cellular accumulation of cisplatin in OVCAR-3, SKOV-3, A2780 (wild-type) and CP70 (A2780/CP70, cisplatin-resistant) cells. Results: Encapsulation efficiency of cisplatin ranged from 5.33% to 21.10%. In vitro cytotoxic activity revealed that IC 50 values of dendrimer-cisplatin complexes were significantly lower than that of free cisplatin in OVCAR-3, SKOV-3 and CP70 cell lines. Cellular uptake data showed highest accumulation of platinum by PAMAMG 4 NH 2 dendrimer complexes of cisplatin in A2780 (19.41±0.85 μg/ml) and CP70 (25.25±1.25 μg/ml) cell lines in comparison with cisplatin uptake of only 1.77±0.351 μg/ml in A2780 and 2.31±0.421 μg/ml in CP70 cells. Conclusion: In conclusion, biotinylated PAMAM dendrimers may be utilized as potential targeting agents for cisplatin delivery to ovarian cancer.

Original languageEnglish (US)
Pages (from-to)897-906
Number of pages10
JournalAnticancer Research
Volume31
Issue number3
StatePublished - Mar 1 2011
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Cisplatin
Dendrimers
Cell Line
PAMAM Starburst
Platinum

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Yellepeddi, V. K., Kumar, A., Maher, D. M., Chauhan, S., Vangara, K. K., & Palakurthi, S. (2011). Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: Role of SMVT. Anticancer Research, 31(3), 897-906.

Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer : Role of SMVT. / Yellepeddi, Venkata K.; Kumar, Ajay; Maher, Diane M.; Chauhan, Subhash; Vangara, Kiran K.; Palakurthi, Srinath.

In: Anticancer Research, Vol. 31, No. 3, 01.03.2011, p. 897-906.

Research output: Contribution to journalArticle

Yellepeddi, VK, Kumar, A, Maher, DM, Chauhan, S, Vangara, KK & Palakurthi, S 2011, 'Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: Role of SMVT', Anticancer Research, vol. 31, no. 3, pp. 897-906.
Yellepeddi VK, Kumar A, Maher DM, Chauhan S, Vangara KK, Palakurthi S. Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: Role of SMVT. Anticancer Research. 2011 Mar 1;31(3):897-906.
Yellepeddi, Venkata K. ; Kumar, Ajay ; Maher, Diane M. ; Chauhan, Subhash ; Vangara, Kiran K. ; Palakurthi, Srinath. / Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer : Role of SMVT. In: Anticancer Research. 2011 ; Vol. 31, No. 3. pp. 897-906.
@article{b1d620479e02467eb4426cdeac9876af,
title = "Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: Role of SMVT",
abstract = "Aim: The aim of this study was to prepare biotinylated PAMAM dendrimers loaded with cisplatin and to evaluate the cytotoxicity in ovarian cancer cell lines. Materials and Methods: Biotinylated and unconjugated dendrimer-cisplatin complexes were investigated for encapsulation efficiency, in vitro cytotoxic activity and cellular accumulation of cisplatin in OVCAR-3, SKOV-3, A2780 (wild-type) and CP70 (A2780/CP70, cisplatin-resistant) cells. Results: Encapsulation efficiency of cisplatin ranged from 5.33{\%} to 21.10{\%}. In vitro cytotoxic activity revealed that IC 50 values of dendrimer-cisplatin complexes were significantly lower than that of free cisplatin in OVCAR-3, SKOV-3 and CP70 cell lines. Cellular uptake data showed highest accumulation of platinum by PAMAMG 4 NH 2 dendrimer complexes of cisplatin in A2780 (19.41±0.85 μg/ml) and CP70 (25.25±1.25 μg/ml) cell lines in comparison with cisplatin uptake of only 1.77±0.351 μg/ml in A2780 and 2.31±0.421 μg/ml in CP70 cells. Conclusion: In conclusion, biotinylated PAMAM dendrimers may be utilized as potential targeting agents for cisplatin delivery to ovarian cancer.",
author = "Yellepeddi, {Venkata K.} and Ajay Kumar and Maher, {Diane M.} and Subhash Chauhan and Vangara, {Kiran K.} and Srinath Palakurthi",
year = "2011",
month = "3",
day = "1",
language = "English (US)",
volume = "31",
pages = "897--906",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer

T2 - Role of SMVT

AU - Yellepeddi, Venkata K.

AU - Kumar, Ajay

AU - Maher, Diane M.

AU - Chauhan, Subhash

AU - Vangara, Kiran K.

AU - Palakurthi, Srinath

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Aim: The aim of this study was to prepare biotinylated PAMAM dendrimers loaded with cisplatin and to evaluate the cytotoxicity in ovarian cancer cell lines. Materials and Methods: Biotinylated and unconjugated dendrimer-cisplatin complexes were investigated for encapsulation efficiency, in vitro cytotoxic activity and cellular accumulation of cisplatin in OVCAR-3, SKOV-3, A2780 (wild-type) and CP70 (A2780/CP70, cisplatin-resistant) cells. Results: Encapsulation efficiency of cisplatin ranged from 5.33% to 21.10%. In vitro cytotoxic activity revealed that IC 50 values of dendrimer-cisplatin complexes were significantly lower than that of free cisplatin in OVCAR-3, SKOV-3 and CP70 cell lines. Cellular uptake data showed highest accumulation of platinum by PAMAMG 4 NH 2 dendrimer complexes of cisplatin in A2780 (19.41±0.85 μg/ml) and CP70 (25.25±1.25 μg/ml) cell lines in comparison with cisplatin uptake of only 1.77±0.351 μg/ml in A2780 and 2.31±0.421 μg/ml in CP70 cells. Conclusion: In conclusion, biotinylated PAMAM dendrimers may be utilized as potential targeting agents for cisplatin delivery to ovarian cancer.

AB - Aim: The aim of this study was to prepare biotinylated PAMAM dendrimers loaded with cisplatin and to evaluate the cytotoxicity in ovarian cancer cell lines. Materials and Methods: Biotinylated and unconjugated dendrimer-cisplatin complexes were investigated for encapsulation efficiency, in vitro cytotoxic activity and cellular accumulation of cisplatin in OVCAR-3, SKOV-3, A2780 (wild-type) and CP70 (A2780/CP70, cisplatin-resistant) cells. Results: Encapsulation efficiency of cisplatin ranged from 5.33% to 21.10%. In vitro cytotoxic activity revealed that IC 50 values of dendrimer-cisplatin complexes were significantly lower than that of free cisplatin in OVCAR-3, SKOV-3 and CP70 cell lines. Cellular uptake data showed highest accumulation of platinum by PAMAMG 4 NH 2 dendrimer complexes of cisplatin in A2780 (19.41±0.85 μg/ml) and CP70 (25.25±1.25 μg/ml) cell lines in comparison with cisplatin uptake of only 1.77±0.351 μg/ml in A2780 and 2.31±0.421 μg/ml in CP70 cells. Conclusion: In conclusion, biotinylated PAMAM dendrimers may be utilized as potential targeting agents for cisplatin delivery to ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=79956141116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956141116&partnerID=8YFLogxK

M3 - Article

C2 - 21498711

AN - SCOPUS:79956141116

VL - 31

SP - 897

EP - 906

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3

ER -